Objective: To describe associations of functional, psychosocial, medical, and sociodemographic factors with performance on a cognitive screening test in chemotherapy naïve patients with breast cancer. Results: In a sample of 331 women with breast cancer, the mean age was 65.2 years and 68.6% were 65 and older. Mean BOMC score was 3.60 on a scale from 0 (best) to 28 (worst). After controlling for demographic factors, worse BOMC screening test results were associated with KPS < 80 (P = 0.01), IADL<14 (P = 0.02), TUG ≥14 seconds (P = 0.001), worse MOS Physical Function (P = 0.0006), depressive symptoms (P = 0.04), and social activity limitations (P = 0.01).
Study participants were drawn from three studies, all of which included the completion of a brief Geriatric Assessment (GA) developed by Hurria and colleagues 11 that is well-validated in cooperative group trials as well as academic and community oncology clinics. 16, 17 The first study is an institutional registry ("Carolina Senior", NCT01137825) of adults age 65 and older with cancer. The other two studies are ongoing intervention trials in women diagnosed with breast cancer who are under age 65 (NCT02167932) or 65 and older (NCT02328313) and are scheduled for chemotherapy. These intervention trials required participants to be capable of light walking. None of the studies had additional inclusion/exclusion criteria, including any requirements related to cognitive function. From all three studies, only female patients with stage I to III breast cancer, who were chemotherapy naïve, were included in this analysis. Participants provided written informed consent and had to be English-speaking to complete study questionnaires. The studies were approved by the Institutional Review Board of the University of North Carolina (IRB Numbers 13-3984, 14-2074, and 09-1512).
| Blessed Memory Orientation Concentration Test (BOMC)
The BOMC is a six-item cognitive screening test that evaluates orientation, language, attention, concentration, and memory. Scores range from 0 to 28 with higher values indicating worse performance. It was originally designed for detection of dementia in elderly subjects.
In non-cancer settings, cut points have been suggested for the presence of dementia and severity of cognitive impairment, 10 but there is no established cut point for use in CRCI.
| Geriatric Assessment
All domains of the GA were included in the study for potential association with the BOMC. [16] [17] [18] The GA includes domains that are administered by a health professional and others that are self-reported.
Domains, measures, and scoring are presented in Table 1 .
2.4 | Health Behavior Questionnaire (HBQ), National Health and Nutrition Survey (NHANES) 20 Study participants were also asked to complete the HBQ, which inquires about current alcohol consumption (none, almost never, yes), smoking history (never, used to, currently), and engagement in vigorous physical activity (causing heavy sweating or large increases in heart rate or breathing).
| Statistical analysis
Descriptive statistics were used to characterize the participants.
Unadjusted linear regression models assessed the bivariate association between BOMC score and functional, psychosocial, medical, and sociodemographic variables. Since there is no validated BOMC threshold for cognitive impairment in cancer populations, BOMC was evaluated as a continuous variable. For each GA variable significant at the P < 0.01 level, a model which adjusted for significant demographic characteristics was fit to see if the association held. For those variables that remained significant in the adjusted model, receiver operating characteristic (ROC) curves were examined to explore a potential threshold BOMC score at which the associations were observed. Pearson correlation coefficients were estimated to assess the linear relationships of BOMC with physical function measures, and a scatter plot is used for visualization. All analyses were conducted using SAS v9.4 statistical software (Cary, NC).
3 | RESULTS
| Patient characteristics
Our final sample consists of 331 women, of whom 184 (65.6%) were from the intervention trials recruiting women who were scheduled for chemotherapy. Participants were mostly white (79.8%) and older (mean age 65.2 years) ( 
| Cognitive screening
The mean BOMC score was 3.60 (range: 0-21). Twenty-eight percent (N = 93) had a BOMC score of 0 (no errors), and >50% of our sample had a score of 2 or less. Over 90% (N = 299) had scores of 8 or less.
3.3 | Association of BOMC with sociodemographic, functional, psychosocial, and medical variables
In unadjusted bivariate analysis, linear regression coefficients in Table 3 indicate how different BOMC scores are for dichotomous and continuous variables. On average, the BOMC score was 1.33 points higher for someone over 65 compared with someone under 65 (P = 0.003). As age was an enrollment criterion in the three studies from which our sample was drawn, this was reflected in the significant association observed between study and BOMC score. Education and In the past 2 weeks-How often the patient felt regarding 9 questions
Higher score ➔ more depressive symptoms (cut point ≥12)
Mental health index-Subscale anxiety 24 In the past 2 weeks-How often the patient felt regarding 4 questions
Higher score ➔ more anxious symptoms (cut point ≥6)
Social activity limitation 23 4 items inquiring about interference with social activities due to physical health or emotional problems Scale 0-100; higher score ➔ more limitations (cut point ≥50)
MOS social support 25 12 items inquiring about having someone who could provide support/help for certain circumstances (eg, if you are confined to a bed) or for personal support (eg, someone who will listen to you when you need to talk) employment status were also strongly associated with cognitive screening scores. Participants with a high school education or less had BOMC scores 2.41 points higher (worse) than those with more education (P < .0001), and participants without full-time employment had scores 2.04 points higher (P < .0001).
Higher physical function, as measured by several tools, was asso- 26 .9% (n = 89) of our cohort would be classified as cognitively impaired.
In our study, we used ROC curves to explore a clinically meaningful BOMC score at which associations with physical function deficits were observed. We found that a BOMC score of six most closely suggested subjective deficits in performance status (Patient-KPS). However, this result must be interpreted with caution given that the area under the curve was not very high (0.73). Although we explored alternative BOMC cut points, because no such threshold has been tested or validated for use in CRCI, we treated BOMC as a continuous variable in assessing its association with various domains of the GA.
It is important to note that even the strongest associations with *P < 0.05 after adjustment for age, employment, and educational level. **P < 0.01 after adjustment for age, employment, and educational level.
***P < 0.001 after adjustment for age, employment, and educational level. show deficits in gait and balance 26 and that reduced gait speed predicts time to onset of cognitive impairment. 27 Further, TUG ≥14 seconds is, in general, highly predictive of morbidity and mortality. 28, 29 Even if further research shows that the score on the BOMC itself is not of unique clinical importance, we anticipate that even subtle changes in this brief, highly practical, screening measure may be meaningful by simply identifying patients in whom investigation of cognitive impairment using self-report measures and neuropsychological assessment is warranted.
| Study limitations
Our study has some limitations. First, the study is cross-sectional and therefore not suited for determinations regarding causality. Second, there are limitations related to the generalizability of our results. Many women in our sample were from intervention studies of patients scheduled to receive chemotherapy. Although these women had not yet received chemotherapy, the selection bias is that women with planned chemotherapy are generally healthier and higher functioning than women who are not scheduled to receive chemotherapy. Sixty percent of participants from the breast cancer intervention trials had undergone surgery prior to their completion of the GA, which must be considered when applying our results to patients with cancer at various stages of treatment. Also related to generalizability, our study was conducted over a period when there were important advances in cancer detection, staging, and therapy. Further, because our study did not include a non-cancer control group, we cannot comment whether the associations we found are unique to patients with cancer. Finally, we were unable to collect information on disease stage to assess the impact of disease severity on cognitive screening.
Other limitations of our study are related to the BOMC. As previously noted, the current BOMC cut point warrants further investigation not only in cancer, but also in younger patient samples. There is also some concern that the BOMC may be less specific in African American and less educated populations. 30 Finally, although the BOMC does screen for the domains most commonly affected in CRCI (memory, concentration, language, and attention), it does not assess verbal fluency or executive function, which the International Cognition and Cancer Task Force recommends for evaluation. 31 
| Clinical implications and future directions
The results of our study have several implications for the care of patients with cancer. First, the BOMC entails minimal time to routine medical examination, requires no special equipment or training, and should be feasible to incorporate in oncology clinic settings. 17 Further research is needed regarding the appropriate cut point for CRCI. Finally, the potential interrelatedness of these domains highlights an opportunity for interventions to preserve both physical and cognitive function. There is some evidence that physical activity is helpful in treating CRCI 32, 33 ; however, research evaluating the impact of physical activity on objectively measured cognitive function and in patients during the acute phase of cancer treatment is needed.
